XML 24 R15.htm IDEA: XBRL DOCUMENT
v3.22.1

Share-Based Compensation Plans | 3 Months Ended
--- | ---
Mar. 31, 2022
Share-Based Compensation Plans |
Share-Based Compensation Plans | 11. Share-Based Compensation Plans During the three months ended March 31, 2022, the Company recognized $350,000 of compensation expense associated with stock option and restricted stock awards granted in years 2017 through 2021. During the three months ended March 31, 2021, the Company recognized $545,000 of compensation expense associated with stock option and restricted stock awards granted in years 2015 through 2020. The following table summarizes the Company’s stock option activity for the three-month period ended March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | ​ | ​ | Exercise | ​ | Contractual | ​ | Intrinsic
​ |  | Shares |  | Price |  | Term (Years) |  | Value*
Outstanding at December 31, 2021 |  | 1,279,833 | ​ | $ | 25.44 |  |  |  | ​ |
Granted |  | — | ​ | ​ | — |  |  |  | ​ |
Exercised |  | (500) | ​ | ​ | 18.00 |  |  |  | ​ |
Forfeited or expired |  | (5,740) | ​ | ​ | 22.82 |  |  |  | ​ |
Outstanding at March 31, 2022 |  | 1,273,593 | ​ | $ | 25.46 |  | 5.4 | ​ | $ | 1,530,000
Exercisable at March 31, 2022 |  | 767,622 | ​ | $ | 26.59 |  | 3.5 | ​ | $ | 336,000
* The aggregate intrinsic value of outstanding and exercisable stock options is defined as the difference between the market value of the Company’s stock on March 31, 2022 of $24.72 and the exercise price multiplied by the number of in-the-money outstanding and exercisable stock options. The following table summarizes the Company’s restricted stock award activity for the three-month period ended March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | Average | ​ | ​ | ​
​ | ​ | Shares of | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | Restricted | ​ | Grant Date | ​ | Contractual | ​ | Intrinsic
​ |  | Stock |  | Fair Value |  | Term (Years) |  | Value*
Non-vested at December 31, 2021 |  | 78,470 | ​ | $ | 23.11 |  |  |  | ​ |
Issued |  | — | ​ | ​ | — |  |  |  | ​ |
Vested |  | (150) | ​ |  | 28.77 |  |  |  | ​ |
Forfeited |  | — | ​ |  | — |  |  |  | ​ |
Non-vested at March 31, 2022 |  | 78,320 | ​ | $ | 23.10 |  | 2.5 | ​ | $ | 1,936,000
* The aggregate intrinsic value of non-vested restricted stock was calculated using the market value of the Company’s stock on March 31, 2022 of $24.72 multiplied by the number of non-vested restricted shares outstanding.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration